4,353 Shares in Boston Scientific Corporation (NYSE:BSX) Purchased by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,353 shares of the medical equipment provider's stock, valued at approximately $439,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG increased its position in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE increased its position in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the last quarter. Jones Financial Companies Lllp increased its position in Boston Scientific by 66.1% in the fourth quarter. Jones Financial Companies Lllp now owns 15,376 shares of the medical equipment provider's stock worth $1,373,000 after purchasing an additional 6,118 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Boston Scientific in the fourth quarter worth $214,000. Institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president owned 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 461,970 shares of company stock worth $47,755,193. Corporate insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

BSX has been the subject of several recent analyst reports. Robert W. Baird lifted their price objective on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Royal Bank Of Canada boosted their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. BTIG Research reissued a "buy" rating and set a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. Finally, Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Twenty-two research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and an average target price of $116.09.

Boston Scientific Stock Down 1.5%

Shares of BSX traded down $1.52 during mid-day trading on Tuesday, hitting $102.31. 6,083,826 shares of the company traded hands, compared to its average volume of 6,667,479. Boston Scientific Corporation has a 1-year low of $71.88 and a 1-year high of $107.53. The business has a 50 day moving average of $103.45 and a 200 day moving average of $100.32. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $151.36 billion, a PE ratio of 74.68, a price-to-earnings-growth ratio of 2.71 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the company earned $0.56 EPS. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.